It looked like we could have gotten some momentum but it was not quite able to continue. It was not stock specific but pretty broad based. It is not as if it was a particularly bad day but that momentum that was building that I thought could get us to the $140-1 level on the […]
May 13th Biotech Update
The sector has been doing pretty well the past couple of days and that is in light of the broader market being pretty bad. That could be good sign and ideally we need to see that outperformance to continue on days in which the broader market is green. Today could be the day to test […]
Week’s Option Activity (12/11~12/20)
The following stocks had notable activity in their options during the past week(s): $ARRY (12/11): 3,500 DEC/MAR 5.0 strike Put Time spreads (stock at $5.09) were sold for a net credit of 0.50 or total proceeds of $175,000. Seller makes money if stock stays above $4.50 by March expiration. $CNDO (12/13): 1,500 MAY 2.50 strike […]
ASH 2013 Preview on Lymphoid Malignancies
This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking the biotech sector’s run the past 2 years. They are now within months of receiving approval for 2 indications where they could benefit patient lives […]
ASH 2013 Preview on Multiple Myeloma
This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs on the backs of Pharmacyclic’s Ibrutinib (stock is up 1000% since ASH11), Celgene’s Revlimid (~67% of their $6.3B 2013 revenue) and Amgen’s $10.6B deal for […]
Preview of ASCO2013 Take One
With the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) rapidly approaching, we want to take the time to present our highlights of the meeting. This is one of the largest medical meetings investors focus upon in the biotech and healthcare sectors. Before we get into this, we do have some overarching […]
Highlights from Day 2 at Needham
Today marked the end of the 12th Annual Needham Healthcare Conference. Below is a collection of slides from companies that we are following or have an interest in. These include Chelsea Therapeutics (CHTP), Curis (CRIS), Cytokinetics (CYTK), Intercept (ICPT), Omeros (OMER), Sangamo (SGMO), TG Therapeutics (TGTX) and several others. (See our slideshow from Day 1 […]
CRIS – Curis Pipeline May Propel Shares
Curis is best known for its hedgehog (Hh) pathway inhibitor Erivedge, which has been licensed to Genentech (Roche). Erivedge was approved for the treatment of inoperable basal cell carcinoma (BCC) in January 2012. The launch has been slow; sales reached only $30.6 million last year. Partnered early, Curis receives only 5% royalties, escalating to high […]
Heat Shock Protein 90 (HSP90) inhibitors: Back in the spotlight – Part 1
Heat Shock Protein 90 (HSP90) was originally proposed as a cancer drug target in the 1990s, though no drug in this class have ever successfully completed a randomized clinical trial, let alone achieve regulatory approval. Despite repeated setbacks, HSP90 inhibitors are poised to find a significant niche in the evolving cancer treatment landscape. We will […]
Updates from the Needham Healthcare Conference
The Needham Healthcare conference was held April 3-4, 2012, and as usual, find my notes below. The webcasts can be accessed at this link with the username “needham” and password “healthcare.” Remember that you can always search with a ticker symbol or keyword in the upper right corner of the Chimera site to bring up all articles […]
CRIS – Updates from Curis 2011 year-end conference call
Curis (NASDAQ: CRIS) currently trades with an enterprise valuation slightly over $300m. The company’s best known asset is the Hedgehog inhibitor vismodegib (ERIVEDGE) which was recently approved for advanced basal cell carcinoma (BCC) and launched by Roche/Genentech ($5.5m in sales were booked in 1q-2012 representing about the first 6 weeks on the market). This article […]
Updates from the Roth Captial Partners Growth Conference
The annual Roth Capital Partners Growth Conference was held March 11-14, 2012. Find the complete presentation schedule and links to webcasts here. Isis Pharma (NASDAQ: ISIS) KYNAMRO (mipomersen) NDA will be filed in the next few weeks before end of quarter (missing this guidance would destroy the last shred of credibility ISIS management has […]
Updates from the Cowen & Co. Healthcare Conference
The early spring biotech investor conference calendar continued with the annual Cowen & Co. Healthcare Conference held March 5-7, 2012 in Boston, MA. As always, my webcast notes below contain only key updates, changes, or new information, and do not represent a complete reprise of any presentation. Additional details on many of these companies can […]
ASCO 2012: American Society of Clinical Oncology Preview Part 2
The 2012 American Society of Clinical Oncology (ASCO) Annual Meeting[link] will take place from June 1st to 5th in Chicago. This is the world’s largest meeting of oncology professionals where some of the industry’s most important data presentations will take place. With conferences like these, come the abstracts releases for presentations; this year abstracts will […]
